Opinion
Video
Author(s):
Panelists discuss how the recently FDA-approved SPN-830 apomorphine infusion pump demonstrated significant efficacy in reducing off time and improving motor function in the INFUS-ON study, with physicians expressing optimistic views about both the US and European clinical trial results.
Video content above is prompted by the following:
SPN-830 FDA Approval and INFUS-ON Study
INFUS-ON Study Design:
Efficacy Results:
Safety Results:
Physician Impressions:
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.